Zeprumetostat for relapsed or refractory PTCL
Part of Blood & lymphatic, Cancer clinical trials.
This trial tests a new drug, Zeprumetostat, in people with a type of lymphoma called PTCL that has come back or not responded to prior treatment. The study looks at how well the drug works and if it is safe.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old.
- You must have been diagnosed with a specific type of PTCL (PTCL-NOS or TFHL) that came back or didn't get better after at least one previous treatment.
- You must have an ECOG performance status of 0, 1, or 2, meaning you are up and active, even if you need to rest some of the day.
- Your life expectancy is more than 3 months.
- Your major organs (like liver, kidneys, and bone marrow) must be working well enough.
- You must agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests two new drugs combined together to treat follicular lymphoma (a slow-growing blood cancer). The trial enrolls patients who have never been treated, those with limited disease who want active treatment, and those whose cancer came back or didn't respond to prior therapy.
This trial tests a combination of targeted drugs, including an EZH2 inhibitor, for people with peripheral T-cell lymphoma that did not respond to initial chemotherapy. It is designed for patients whose tumor has been genetically tested to guide treatment.
This trial tests a new drug combination for people with certain types of lymphoma that have not responded to standard treatments. The drug, zeprumetostat, targets a protein called EZH2 to help stop cancer growth.
This trial tests a combination of two drugs (tislelizumab and zeprumetostat) for people whose NK/T-cell lymphoma has returned or stopped responding to previous treatment. The goal is to see if the combination works better than what has been tried before.
This trial tests a combination of three drugs (zeprumetostat, azacitidine, and a liposomal form of mitoxantrone) for people with a type of lymphoma called peripheral T-cell lymphoma that has come back or not responded to treatment. The goal is to see if this combination can help shrink or control the lymphoma.
This trial is testing a combination of two targeted drugs (linperlisib and an EZH2 inhibitor) for people whose peripheral T-cell lymphoma has come back or not responded to previous treatment. The goal is to see if this new combination can help shrink tumors and slow the disease.
Hear when a new PTCL-NOS trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.